New Bioactive Cerebrosides from *Arisaema amurense*

Jee H. Jung*

Korea Ocean Research & Development Institute, Seoul 425-600, Korea

Chong-Ock Lee

Korea Reseach Institute of Chemical Technology, Taejeon 305-606, Korea

Young Choong Kim

College of Pharmacy, Seoul National University, Seoul 151-742, Korea

Sam Sik Kang

Natural Products Research Institute, Seoul National University, Seoul 110-460, Korea

Received September 19, 1995[⊗]

From *Arisaema amurense*, four new cerebrosides were isolated along with a known cerebroside. The new cerebrosides were characterized as 1-*O*-*β*-D-glucopyranosyl-(2*S*,3*R*,4*E*,8*Z*)-2-[(2(*R*)-hydroxyicosanoyl)amido]-4,8-octadecadiene-1,3-diol (**1**), 1-*O*-*β*-D-glucopyranosyl-(2*S*,3*R*,4*E*,8*Z*)-2-[(2-hydroxyoctadecanoyl)amido]-4,8-octadecadiene-1,3-diol (**2**), 1-*O*-*β*-D-glucopyranosyl-(2*S*,3*R*,4*E*,8*E*)-2-[(2-hydroxyicosanoyl)amido]-4,8-octadecadiene-1,3-diol (**4**), and 1-*O*-*β*-D-glucopyranosyl-(2*S*,3*R*,4*E*,8*E*)-2-[(2-hydroxyoctadecanoyl)amido]-4,8-octadecadiene-1,3-diol (**5**), respectively. These cerebrosides displayed significant antihepatotoxic activity.

Arisaema amurense Maxim. (Araceae), a perennial herb, is known as a toxic plant in folklore. In this report, we describe the isolation and structure determination of four new cerebrosides (**1**, **2**, **4**, and **5**) along with a known cerebroside (**3**).[1−4]

Dried roots of *A. amurense* were cut into small pieces and extracted with acetone. The acetone extract was concentrated *in vacuo*, and the resulting residue was partitioned between H_2O and CH_2Cl_2. The CH_2Cl_2 phase was concentrated and further partitioned between 90% aqueous MeOH and *n*-hexane. The alcoholic phase was subjected to successive C-18 reversed-phase chromatography to yield cerebrosides **1**−**5**.



^{1}H and ^{13}C NMR data of **1** (Table 1) indicated the presence of a sugar residue, an amide linkage, and aliphatic long chain(s), strongly suggesting the glycosphingolipid nature of **1**. In the ^{13}C NMR spectrum of **1**, the signals at δ 104.7, 75.0, 77.9 (two carbons), 71.5, and 62.7 suggested that the sugar in **1** was a *β*-glucopyranoside. The coupling constant between H-1″ [δ 4.26 (d, $J = 8.0$ Hz)] and H-2″ [δ 3.19 (dd, $J = 8.0$, 9.0 Hz) also supports the *β*-configuration of the sugar. Methanolysis of **1** gave a mixture of α- and *β*-methyl glucopy-

Table 1. [1]H (500 MHz) and ^{13}C (50 MHz) NMR Data of **1** (CD_3OD)

position	^{1}H NMR δ (m, *J* in Hz)	^{13}C NMR, δ	COSY correlation
1a	4.11 (dd, 10.1, 5.8)	69.7	1b, 2
1b	3.71 (dd, 10.1, 3.7)	69.7	1a, 2
2	3.99 (ddd, 5.8, 3.7, 1.9)	54.6	1a, 1b, 3
3	4.14 (td, 7.5, 1.9)	72.9	2, 4
4	5.49 (dd, 15.1, 7.5)	129.9	3, 5
5	5.73 (dtd, 15.1, 6.2, 1.5)	134.3	4, 6
6	2.07 (m)	33.7	5, 7
7	2.12 (m)	28.0	6, 8
8, 9	5.37 (t, 5.1)	131.3	7, 10
10	2.05 (m)	28.3	9, 11
11	1.35 (m)	33.1, 31.0, 30.8, 30.5, 30.3, 30.2, 26.2, 23.7	
12−17	1.30 (m)		
1″	4.26 (d, 8.0)	104.7	2″
2″	3.19 (dd, 9.0, 8.0)	75.0	1″, 3″
3″	3.35 (t, 9.0)	77.9	2″, 4″
4″	3.28[a] (m)	71.5	3″, 5″
5″	3.27[a] (m)	77.9	6″a, 6″b
6″a	3.86 (dd, 12.0, 2.8)	62.7	6″b, 5″
6″b	3.67 (dd, 12.0, 5.8)	62.7	6″a, 5″
1′		177.1	
2′	3.98 (dd, 8.0, 4.2)	73.0	3′a, 4′b
3′a	1.72 (m)	35.8	2′, 4′, 3′b
3′b	1.54 (m)	35.8	2′, 4′, 3′a
4′	1.40 (m)	33.1, 31.0, 30.8, 30.5, 30.3, 30.2, 26.2, 23.7	5′, 3′a, 3′b
5′−19′	1.30 (m)		
CH_3	0.90 (6H, t, 7.0)	14.5	

[a] Assignments may be reversed.

[⊗] Abstract published in *Advance ACS Abstracts,* March 1, 1996.

 © 1996 American Chemical Society and American Society of Pharmacognosy



Figure 1. Partial structure of **1**.

ranoside. The optical rotation of the methyl glucoside mixture $[\alpha]^{25}_{D}$ +75.6° (c = 0.18, MeOH) was close to that of authentic sample, $[\alpha]^{25}_{D}$ +77.3°,[5] defining glucose as the D-isomer. A signal of a carbon attached to nitrogen was observed at δ 54.6, and an amide carbonyl signal appeared at δ 177.1 in the ^{13}C NMR spectrum. An intense signal at δ 1.30 and the triplet at δ 0.90 (6H, t, J = 7.0 Hz) in the ^{1}H NMR spectrum suggested the presence of one or more long aliphatic chains. COSY and homonuclear J-resolved 2D experiments on **1** established the partial structure shown in Figure 1. The 4,5 alkene bond was found to be *trans*, as evidenced by the large vicinal coupling constants ($J_{4,5}$ = 15.1 Hz). The *trans* geometry of this double bond was also supported by the chemical shift of C-6 (δ 33.7). Usually, the signals of carbons next to a *trans* double bond appear at δ 32−33, while those of a *cis* double bond appear at δ 27−28.[6] The olefinic protons at 8, 9 were magnetically equivalent, but as evidenced by the carbon signals of C-7 (δ 28.0) and C-10 (δ 28.3), the geometry of the 8,9 alkene bond was determined to be *cis*. The positive FABMS of **1** gave peaks at m/z 792 [M + Na]$^+$, 770 [M + H]$^+$, and 752 [(M + H) − H_2O]$^+$. A peak at m/z 590 [[(M + H) − H_2O] − 162]$^+$ indicated the loss of a hexose unit from the [M + H]$^+$ ion. In the ^{13}C NMR spectrum of **1**, another CH signal appeared at δ 73.0 (C-2′ in acyl moiety), and the corresponding proton at δ 3.98 (1H, dd, J = 8.0, 4.2 Hz) showed coupling with methylene protons (H-3′). The acyl moiety is hence an α-hydroxyl linear acyl chain. The relative stereochemistry of **1** at C-2 and C-3 was predicted to be the same as that of D-sphingosine (D-*erythro*), on the basis of the ^{13}C NMR spectral data, since the chemical shifts of C-2 (δ 54.6) and C-3 (δ 72.9) were in agreement with those of synthetic *N*-octadecanoyl-D-*erythro*-sphingosine (δ 54.7, 73.1)[7] and glucosyl-*erythro*-ceramide (δ 53.8, 72.6).[8] Methanolysis of **1** afforded methyl 2-hydroxyicosanoate. Its optical rotation ($[\alpha]^{25}_{D}$ −3.5°, c = 0.09, $CHCl_3$)[9] identified it as the *R* isomer. Thus, the structure of **1** was assigned as 1-*O*-β-D-glucopyranosyl-(2*S*,3*R*,4*E*,8*Z*)-2-[(2(*R*)-hydroxyicosanoyl)amido]-4,8-octadecadiene-1,3-diol.

The ^{1}H NMR spectrum of **2** was almost identical with that of **1**, indicating only subtle differences in the chain length of the α-hydroxy fatty acid moiety and/or long-chain base. In the positive FABMS of **2**, peaks at m/z 764 [M + Na]$^+$, 742 [M + H]$^+$, 724 [(M + H) − H_2O]$^+$, and 562 [[(M + H) − H_2O] − 162]$^+$ were observed. Methanolysis of **2** afforded methyl 2-hydroxyoctadecanoate. Accordingly, the structure of **2** was assigned as 1-*O*-β-D-glucopyranosyl-(2*S*,3*R*,4*E*,8*Z*)-2-[(2-hydroxyoctadecanoyl)amido]-4,8-octadecadiene-1,3-diol.

The ^{1}H NMR spectrum of **3** was also almost identical with those of **1** and **2**, indicating only subtle differences in the chain length of the α-hydroxy fatty acid moiety and/or long-chain base. In a positive FABMS of **3**, peaks at m/z 736 [M + Na]$^+$, 714 [M + H]$^+$, and 696 [(M + H) − H_2O]$^+$ were observed. Methanolysis of **3** afforded methyl 2-hydroxyhexadecanoate. Accordingly, the structure of **3** was identified as 1-*O*-β-D-glucopyranosyl-(2*S*,3*R*,4*E*,8*Z*)-2-[(2-hydroxyhexadecanoyl)amido]-4,8-octadecadiene-1,3-diol, which has been previously isolated from various plant sources.[1−4]

Table 2. ^{1}H (500 MHz) and ^{13}C (125 MHz) NMR Data of **4** (CD_3OD)

position	^{1}H NMR δ (m, J in Hz)	^{13}C NMR, δ	COSY correlation
1a	4.10 (dd, 10.1, 5.2)	69.7	1b, 2
1b	3.70 (dd, 10.1, 3.8)	69.7	1a, 2
2	3.98 (ddd, 5.8, 3.7, 2.0)	54.6	1a, 1b, 3
3	4.13 (td, 8.3, 1.5)	72.9	2, 4
4	5.47 (dd, 15.5, 7.6)	130.7	3, 5
5	5.72 (br. d, 15.5)	134.4	4, 6
6, 7	2.07 (m)	33.71, 33.67	5, 8
8, 9	5.42 (t, 4.9)	132.0, 131.2	7, 10
10	1.98 (m)	33.3	9, 11
11	1.35 (m)	33.1, 30.8, 30.7, 30.5, 30.3, 26.2, 23.7	
12−17	1.30 (m)		
1″	4.26 (d, 7.9)	104.7	2″
2″	3.18 (dd, 9.0, 7.9)	75.0	1″, 3″
3″	3.34 (t, 9.0)	78.0[b]	2″, 4″
4″	3.26[a] (m)	71.6	3″, 5″
5″	3.27[a] (m)	77.9[b]	4″, 6″a, 6″b
6″a	3.86 (dd, 12.1, 1.7)	62.7	5″, 6″b
6″b	3.66 (dd, 12.1, 5.6)	62.7	5″, 6″a
1′		177.2	
2′	3.97 (dd, 8.0, 3.8)	73.1	3′a, 3′b
3′a	1.70 (m)	35.9	2′, 3′b, 4′
3′b	1.55 (m)	35.9	2′, 3′a, 4′
4′	1.40 (m)	33.1, 30.8, 30.7, 30.5 30.3, 26.2, 23.7	3′a, 3′b, 5
5′−19′	1.30 (m)		
CH_3	0.90 (6H, t, 6.9)	14.4	

[a,b] Assignments with the same superscript may be reversed.

The ^{1}H NMR spectral data of **4** exhibited certain differences from those of **1**−**3**. The signal of the olefinic protons at δ 5.37 (H-8, -9, t, J = 5.1 Hz) in **1**−**3** was shifted downfield (δ 5.42, t, J = 4.9 Hz), and the signal of olefinic protons at δ 5.72 (H-5, J = 15.5 Hz) appeared as a broad doublet instead of a doublet of triplet of doublet (δ 5.73, J = 15.1, 6.2, 1.5 Hz) of **1**−**3**. The signals of H-7 and H-19 ranged from δ 2.12 to δ 2.07 and δ 2.05 to δ 1.98, respectively, indicating a possible change in the geometry of the double bond at C-8. A *trans* configuration of 8,9 alkene bond was supported by the downfield shifts of C-7, C-10 carbon signals from δ 28.0, 28.3 to around δ 33.7, 33.3, respectively. The broadening of the H-5, -6, -7, -8, -9, and -10 signals was assumed to be due to greater free rotation along these single bonds in the long-chain base moiety. The positive FABMS of **4** contains peaks at m/z 792 [M + Na]$^+$, 770 [M + H]$^+$, and 752 [(M + H) − H_2O]$^+$ indicating the same molecular weight as **1**. Methanolysis of **4** afforded methyl 2-hydroxyicosanoate. Accordingly, the structure of **4** was assigned as 1-*O*-β-D-glucopyranosyl-(2*S*,3*R*,4*E*,8*E*)-2-[(2-hydroxyicosanoyl)amido]-4,8-octadecadiene-1,3-diol.

The ^{1}H NMR spectrum of **5** was almost identical with those of **4**, indicating only subtle differences in the chain length of the α-hydroxy fatty acid moiety and/or long-chain base. The positive FABMS of **5** had peaks at m/z 764 [M + Na]$^+$, 742 [M + H]$^+$, and 724 [(M + H) − H_2O]$^+$ indicating the same molecular weight as **2**.

Table 3. Antihepatotoxic Activities of Compounds **1**−**5**

compd	GPT assay[c] (%)	SDH assay[c] (%)
ctrl[a]	100 ± 0.1	100 ± 0.1
ctrl[b]	0 ± 0.1	0 ± 0.1
silybin[d]	48.7 ± 0.5	42.3 ± 0.8
1	53.8 ± 0.2[e]	51.2 ± 0.9[e]
2	35.1 ± 0.6	36.9 ± 3.9
3	54.4 ± 0.9[e]	71.2 ± 0.9[f]
4	22.5 ± 0.4	7.2 ± 0.0
5	51.6 ± 0.4[e]	46.1 ± 0.8

[a] Control. [b] Control treated with CCl_4. [c] The percent of activity is calculated as 100 (GPT and SDH activity of ctrl[b]−GPT and SDH activity of sample)/(GPT and SDH activity of ctrl[b] − GPT and SDH activity of ctrl[a]). [d] Silybin was used as a positive control. Each sample was tested at 5 μM concentration. [e] $P < 0.05$. [f] $P < 0.01$.

Methanolysis of **5** afforded methyl 2-hydroxyoctadecanoate. Accordingly, the structure of **5** was assigned as 1-*O*-β-D-glucopyranosyl-(2*S*,3*R*,4*E*,8*E*)-2-[(2-hydroxyoctadecanoyl)amido]-4,8-octadecadiene-1,3-diol.

Sphingosine derivatives and several cerebrosides have been reported to possess cytotoxicity and other bioactivities.[10−12] We tested cerebrosides **1**−**5** for cytotoxicity against human tumor cells such as A549 (lung cancer), SK-OV-3 (ovarian cancer), SK-MEL-2 (melanoma), XF498 (CNS cancer), and HCT15 (colon cancer), but these cerebrosides did not show significant cytotoxicity. However, cerebrosides **1**, **3**, and **5** showed significant antihepatotoxic activity comparable to silybin against CCl_4-induced toxicity in primary cultured rat hepatocytes (Table 3).

Experimental Section

General Experimental Procedures. Optical rotations were measured with a JASCO DIP-360 polarimeter. Solutions in CD_3OD were used for all the NMR studies. Chemical shifts were reported relative to the residual solvent peaks (CD_3OD: δ 3.3, δ 49). ^{1}H NMR, COSY, TOCSY, and homonuclear *J*-resolved 2D experiments were recorded at 500 MHz with a Varian Unity 500 instrument using Varian standard pulse programs. ^{13}C NMR and HETCOR spectra were recorded at 125 MHz with a Varian Unity 500 or at 50 MHz with a Varian VXR-200S instrument. FABMS were measured on JMS-SX 102 mass spectrometer with a direct inlet system using glycerol as a matrix. Europrep 60-60 (Knauer) was used for reversed-phase flash column chromatography. YMC-pack ODS-A (7 μm, 250 × 10 mm) column was used with Alltech guard catridge column for HPLC. RP-18 F_{254} S (Merck) was used for TLC.

Plant Material. *A. amurense* was collected in Chirisan, Korea, in May 1993, and identified by Dr. Hyung Joon Chi, Natural Products Research Institute, Seoul National University. A voucher specimen was deposited at the herbarium of the Natural Products Research Institute (NAPRI-94-04-13). Field-collected material (210 g) was used for the pilot experiment. For the main separation procedure, dried roots of *A. amurense* were purchased from a commercial supplier.

Extraction and Isolation. Dried roots of *A. amurense* (3.6 kg) were cut into small pieces and extracted with acetone at room temperature. The acetone extract was concentrated under vacuum, and the resulting residue was partitioned between H_2O and CH_2Cl_2. The CH_2Cl_2 partition was concentrated and further partitioned between 90% aqueous MeOH and *n*-hexane. The 90% aqueous MeOH partition was subjected to C-18 reversed-phase flash column chromatography. The column was eluted in the sequence of MeOH:CH_3CN (10:1) → MeOH:CH_3CN (10:3) → MeOH:CH_3CN (10:5) → MeOH:CH_3CN (10:10) → CH_3CN → CH_3CN:CH_2Cl_2 (1:1) → CH_2Cl_2 → CH_2Cl_2:*n*-hexane (1:1) → *n*-hexane. A total of nine fractions were obtained. Fraction 2 (1.31 g) was further subjected to C-18 reversed-phase gravity column chromatography, eluted with MeOH:CH_3CN (10:1), MeOH:CH_3CN (2:1), and CH_3CN. A total of eight fractions were obtained from which fractions 4 (420 mg) and 5 (360 mg) were further subjected to C-18 reversed-phase HPLC [mobile phase MeOH:CH_3CN (5:3), flow rate 2.4 mL/min] equipped with refractive index monitor to afford **1** (53.6 mg), **2** (46.5 mg), **3** (0.8 mg), **4** (10 mg), and **5** (3 mg). The retention time for each compound was as follows: **1** (74.6 min), **2** (47 min), **3** (32.4 min), **4** (76.8 min), and **5** (49.4 min).

Cerebroside 1: colorless amorphous powder; positive FABMS *m/z* 792 $[M + Na]^+$, 770 $[M + H]^+$, 752 $[(M + H) - H_2O]^+$, 590 $[[(M + H) - H_2O] - 162]^+$; $[\alpha]^{25}_D$ +17° (c = 0.085, MeOH); ^{1}H and ^{13}C NMR, see Table 1.

Methanolysis of 1. A solution of **1** (15.5 mg) in 5% HCl−MeOH (5 mL) was refluxed for 7 h. The reaction mixture was extracted with *n*-hexane. The *n*-hexane layer was concentrated under reduced pressure to yield fatty acid methyl ester (methyl 2-hydroxyicosanoate) (6.3 mg); $[\alpha]^{25}_D$ −3.5° (c = 0.09, $CHCl_3$); ^{1}H NMR ($CDCl_3$, 500 MHz) δ 0.89 (t, J = 7.0 Hz, CH_3), 1.26 (long chain $-CH_2-$), 2.69 (d, J = 5.9 Hz, OH), 3.79 (s, $COOCH_3$), 4.20 (ddd, J = 4.3, 5.9, and 7.5 Hz, H-2), 1.78 (m, H-3), 1.63 (m, H-4); EIMS *m/z* (rel int) 342 (M^+, 88), 283 ($M^+ - COOCH_3$, 81). The aqueous MeOH layer of the hydrolysate was evaporated under reduced pressure to remove residual HCl. The resulting residue was partitioned between H_2O and EtOAc. The H_2O layer was concentrated (6.3 mg) and purified on a C-18 reversed-phase column to afford methyl glucopyranoside (mixtures of anomers, 3.5 mg): $[\alpha]^{25}_D$ +75.6° (c = 0.18, MeOH); ^{1}H NMR (CD_3OD, 500 MHz) δ 4.66 (H-1, α-anomer, d, J = 3.8 Hz), 4.16 (H-1, β-anomer, d, J = 7.8 Hz), 3.52 (OCH_3, β-anomer), 3.39 (OCH_3, α-anomer).

Cerebroside 2: colorless amorphous powder, positive FABMS *m/z* 764 $[M + Na]^+$, 742 $[M + H]^+$, 724 $[(M + H) - H_2O]^+$, 562 $[[(M + H) - H_2O] - 162]^+$. Methanolysis of **2** (0.4 mg) afforded methyl 2-hydroxyoctadecanoate: EIMS *m/z* (rel int) 314 (M^+, 73), 255 ($M^+ - COOCH_3$, 100).

Cerebroside 3: colorless amorphous powder; positive FABMS *m/z* 737 $[M + Na]^+$, 714 $[M + H]^+$, 696 $[(M + H) - H_2O]^+$. Methanolysis of **3** (0.4 mg) afforded methyl 2-hydroxyhexadecanoate: EIMS *m/z* (rel int) 286 (M^+, 35), 227 ($M^+ - COOCH_3$, 81).

Cerebroside 4: colorless amorphous powder; positive FABMS *m/z* 792 $[M + Na]^+$, 770 $[M + H]^+$, 752 $[(M + H) - H_2O]^+$; ^{1}H and ^{13}C NMR, see Table 2. Methanolysis of **4** (0.5 mg) afforded methyl 2-hydroxyicosanoate: EIMS *m/z* (rel int) 342 (M^+, 100), 283 ($M^+ - COOCH_3$, 94).

Cerebroside 5: colorless amorphous powder; positive FABMS *m/z* 764 $[M + Na]^+$, 742 $[M + H]^+$, 724 $[(M + H) - H_2O]^+$, 562 $[[(M + H) - H_2O] - 162]^+$. Methanolysis of **5** (0.5 mg) afforded methyl 2-hydroxyoctadecanoate: EIMS *m/z* (rel int) 314 (M^+, 83), 255 ($M^+ - COOCH_3$, 100).

Biological Evaluations. The isolated hepatocytes were plated and then were cultured for 1 day. The isolate was exposed to 10 mM CCl_4 for 1.5 h to induce cytotoxicity. The activity of GPT (glutamic pyruvic transaminase) in the culture medium was determined by the method of Reitman−Frankel[13] using an assay kit. The activity of SDH (sorbitol dehydrogenase) in the culture medium was determined by the method of Gerlach[14] with minor modifications.

Acknowledgment. This work was financially supported by the Korean Ministry of Science and Technology Grant. We thank En Mi Do and Doo H. Moon for their devotion to this work and Dr. Jung Rae Rho for measurement of ^{13}C NMR spectra on the Varian VXR-200S instrument.

References and Notes

(1) Okuyama, E.; Yamazaki, M. *Chem. Pharm. Bull.* **1983**, *31*, 2209−2219.
(2) Yoshioka, A.; Etoh, H.; Yagi, A.; Sakata, K.; Ina, K. *Agric. Biol. Chem.* **1990**, *54*, 3355−3356.
(3) Inoue, T.; Sakurai, N.; Nagai, S.; Nagai, M. *Shoyakugaku Zasshi* **1992**, *46*, 261−264.
(4) Shibuya, H.; Kawashima, K.; Sakagami, M.; Kawanishi, H.; Shimomura, M.; Ohashi, K.; Kitagawa, I. *Chem. Pharm. Bull.* **1990**, *38*, 2933−2938.
(5) Jin, W.; Rinehart, K. L.; Jares-Erijman, E. A. *J. Org. Chem.* **1994**, *59*, 144−147.
(6) Stothers, J. B. *Carbon-13 NMR spectroscopy*; Academic Press, Inc.: New York, 1972.
(7) Julina, R.; Herzig, T.; Bernet, B.; Vasella, A. *Helv. Chim. Acta* **1986**, *69*, 368−373.
(8) Sarimentos, F.; Schwarzmann, G.; Sandhoff, K. *Eur. J. Biochem.* **1985**, *146*, 59.
(9) Higuchi, R.; Natori, T.; Komori, T. *Liebigs. Ann. Chem.* **1990**, 51−55.
(10) Kobayashi, J.; Ishibashi, M.; Nakamura, H.; Hirata, Y.; Yamasu, T.; Sasaki, T.; Ohizumi, Y. *Experientia* **1988**, *44*, 800−802.
(11) Carter, G. T.; Rinehart, K. L. *J. Am. Chem. Soc.* **1978**, *100*, 7441−7442.
(12) Natori, T.; Morita, M.; Akimoto, K.; Koezuka, Y. *Tetrahedron* **1994**, *50*, 2771−2784.
(13) Reitman, S.; Frankel, S. *Am. J. Clin. Pathol.* **1957**, *28*, 56−61.
(14) Gerlach, U. In *Methods of Enzymatic Analysis*; Bergmeyer, H. U., Ed.; A. E. Harper: New York, 1965; pp 761−765.

NP960201+